Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Epilepsy
Interventions: Brivaracetam, Lorazepam; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Orlando, Florida + 10 more

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more

Conditions: Neurodevelopmental Outcome
Interventions: iron; Dietary Supplement
Lead sponsor: University of Rochester; Other
Eligibility: Up to 32 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Osteoarthritis, Hip
Interventions: FX006, Normal saline; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 27 more

Conditions: Postpartum Contraception, Family Planning
Interventions: Etonogestrel-Immediate, Etonogestrel-Delayed; Drug
Lead sponsor: Stanford University; Other
Eligibility: Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rhinitis, Allergic, Perennial
Interventions: fluticasone furoate nasal spray, vehicle placebo nasal spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 56
States / cities: Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more

Conditions: Pediatric Cancer
Interventions: "Just Move" Exercise, Standard of Care Exercise; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Sarcoma
Interventions: OMBRABULIN (AVE8062), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 6
States / cities: Santa Monica, California • Orlando, Florida • Maywood, Illinois + 3 more

Conditions: Friedreich Ataxia
Interventions: DT-216, DT-216 matching Placebo; Drug
Lead sponsor: Design Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Chronic Kidney Disease Stage 3B, Chronic Kidney Disease, Stage 4, Proteinuria
Interventions: whole food, plant-based diet; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Parkinson's Disease
Interventions: PYM50028, Placebo; Drug
Lead sponsor: Phytopharm; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 41
States / cities: Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more

Conditions: Glycemic Response, Menopause Symptoms
Interventions: Reducose® (Mulberry leaf extract), Placebo; Dietary Supplement
Lead sponsor: Phynova Group Ltd; Industry
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke, Acute Ischemic Stroke
Interventions: Repinotan HCl (BAYX3702), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 782 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 28
States / cities: Los Angeles, California • Oceanside, California • San Diego, California + 25 more

Conditions: Obesity
Interventions: Semaglutide, Tirzepatide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Seasonal Allergic Rhinitis, Hay Fever
Interventions: Beclomethasone dipropionate, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Postoperative Pain After Uterine Fibroid Embolization, Uterine Fibroids (UF), Uterine Fibroids, Pelvic Pain, Pain Management
Interventions: TUNES (Transmucosal Uterosacral Electrical Stimulation), Sham TUNES Device; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 28 Years to 52 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Leiomyosarcoma
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more

Conditions: Vaccine Uptake
Interventions: Communication Campaign; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Labor Pain
Interventions: Additional Epidural Education; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Radiation Retinopathy
Interventions: 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP); Drug · Procedure
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Katy, Texas + 1 more

Conditions: Healthy Volunteers
Interventions: PF-04308515, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions: Pentoxifylline, Placebo, Tocopherol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DuBois, Pennsylvania

Conditions: Pain, Postoperative, Bunion
Interventions: COV155, placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Pasadena, California • Pasadena, Maryland + 2 more

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Iron Status and Myelination in Premature Infants

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Labor and Delivery Implant Insertion: A Randomized Controlled Trial

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

Repinotan in Patients With Acute Ischemic Stroke

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance

The Effect of a Culturally Sensitive Educational Intervention on Acceptance of Neuraxial Anesthesia

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain